Endocyte announces plans for $60 million at-the-market sales agreement

Agent Cowen and Co. conducts offering and will be paid a 3% commission

By Devika Patel

Knoxville, Tenn., Dec. 23 - Endocyte, Inc. arranged a $60 million at-the-market sales agreement with Cowen and Co., LLC on Dec. 20, according to an 8-K filed Monday with the Securities and Exchange Commission.

Cowen will be paid a 3% commission.

Based in West Lafayette, Ind., Endocyte is a biopharmaceutical company developing targeted small molecule drug conjugates and companion imaging diagnostics for personalized therapy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.